Download Files:
AKT-IN-3
$850 – $7,200
Products Details
Product Description
– AKT-IN-3 (compound E22) is a potent, orally active low hERG blocking Akt inhibitor, with 1.4 nM, 1.2 nM and 1.7 nM for Akt1, Akt2 and Akt3, respectively. AKT-IN-3 (compound E22) also exhibits good inhibitory activity against other AGC family kinases, such as PKA, PKC, ROCK1, RSK1, P70S6K, and SGK. AKT-IN-3 (compound E22) induces apoptosis and inhibits metastasis of cancer cells[1].
Web ID
– HY-126257
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C23H23Cl2F2N5O3
References
– [1]Dong X, et al. Discovery of 3,4,6-Trisubstituted Piperidine Derivatives as Orally Active, Low hERG Blocking Akt Inhibitors via Conformational Restriction and Structure-Based Design. J Med Chem. 2019 Aug 8;62(15):7264-7288.
CAS Number
– 2374740-21-1
Molecular Weight
– 526.36
Compound Purity
– 99.29
SMILES
– CNC(C[C@H]1NC[C@@H](NC(C2=CC(C3=C(Cl)C=NN3C)=C(Cl)O2)=O)[C@H](C4=CC(F)=C(F)C=C4)C1)=O
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : ≥ 100 mg/mL
Target
– Akt;Apoptosis
Isoform
– Akt1;Akt2;Akt3
Pathway
– Apoptosis;PI3K/Akt/mTOR
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
